By By Michael Braunagel, managing director, Actigen
Enzyme replacement therapy (ERT) made its debut in 1991, heralding a breakthrough in medical science for individuals and families grappling with rare diseases stemming from single gene mutations.
The US FDA has changed its sterility testing requirements for biological products to give manufacturers greater flexibility and encourage use of ‘state-of-the-art’ analysis methods.
Cisbio has licensed BellBrook Labs' ADP immunodetection technology
for use in its HTRF screening system that will enable researchers
to study the activity of any protein kinase.
Sigma-Aldrich has launched a new technology that promises to
dramatically simplify and speed-up high-throughput (HT) RNAi
screening of the human kinome.
Celsis' Rapid Microbiological Method (RMM) has been included in GlaxoSmithKline's (GSK) successful Veramyst New Drug Application (NDA), paving the way for broader acceptance of the time saving technique.
Researchers in the US have developed an exciting new tool that
enables scientists to watch cell chemical activity in real-time.
The tool's development has major implications for speeding up new
drug design.
Galapagos and Cellzome have announced the start of a drug discovery
collaboration in which the two companies are to concentrate on
kinases, a popular target for pharmaceutical therapies for cancer
and inflammatory diseases.
German cancer drug company GPC Biotech has agreed to buy the
material assets of Munich-based kinase specialist Axxima
Pharmaceuticals in a cash-neutral transaction for €13.7m.
Researchers have developed a new structural understanding of how
the two key subunits of kinases, one of the most important classes
of enzymes, work together. kinases have increasingly become prime
targets for drugs to treat an array...
QTL Biosystems announced the introduction of its QTL LightSpeed
Kinase platform and four new kinase Activity Assays, which uses a
unique polymer technology that does not require antibodies or
radioactive labels, providing a distinct...
